

GREAT SUCCESS OF NASDAQ IPO OF ABIVAX, A BIOTECH COMPANY FOUNDED BY TRUFFLE CAPITAL

- Truffle Capital congratulates Abivax management team led by Marc de Garidel
- The IPO is expected to be the largest Nasdaq IPO ever for a French biotech company

Paris, October 21st, 2023 - Truffle Capital is pleased with Abivax's highly successful Nasdaq IPO, despite a challenging stock market environment. Abivax is a clinical-stage biotechnology company focused on the development of drugs that exploit the body's natural regulatory mechanisms to modulate the immune response of patients suffering from chronic inflammatory diseases.

For further information, refer to the Abivax <u>press release announcing the pricing of its IPO on the Nasdaq Global Market</u>, and <u>the Abivax website</u>.

Abivax, founded in 2013 by Truffle Capital, had raised 58 million euros during its IPO on Euronext, in 2015. To date, this remains the largest IPO of a biotech company on Euronext Paris.

The IPO announced yesterday is expected to rank as the largest IPO ever carried out by a French biotech company on the Nasdaq. Following this IPO, Abivax is expected to become the third company in the world to have secured the most financing in the biotech sector in 2023.

About Truffle Capital

Founded in 2001, Truffle Capital is an independent European venture capital firm specializing in disruptive technologies in the Life Sciences (Medtech and Biotech) and IT (Fintech and Insurtech) sectors. Truffle Capital's mission is to support the creation and development of innovative young companies capable of becoming tomorrow's leaders.

Chaired by Patrick Kron and managed by Dr Philippe Pouletty, PhD, and Bernard-Louis Roques, Co-founders and Managing Directors, Truffle Capital manages assets of €600m. It has raised more than €1.1 billion since its creation and has supported more than 75 companies in the life sciences and digital technologies sectors.

https://www.truffle.com/

Contact Truffle Capital

Fanny Brugiere | fanny@truffle.com

Primatice Conseil

Thomas de Climens | thomasdeclimens@primatice.com Armand Rigaudy | armandrigaudy@primatice.com